Kornimate/medical-research-clean huggingface dataset:
desensitization protocol for highly sensitized patients on the waiting list for kidney transplant

Conditions: End Stage Renal Disease

Summary: the purpose of this study is to determine whether high dose ivig and b cell depleting agents can be used effectively in highly sensitized wait-listed patients.

hla sensitization is known to be the most important barrier to deceased donor kidney allocation. therefore, the investigators need to develop better strategies for managing pre-sensitized patients using desensitization protocol. in this study the investigators will used two kinds of medication for the reduction of circulating antibodies (high dose ivig, b cell depleting agents) to highly-sensitized patients who are on the waiting list for a deceased donor kidney transplantation. after desensitization, the investigators will check that this treatment can increase their chances of receiving a kidney transplant.

Eligibility criteria:
inclusion criteria: * age ≥ 18 * patients who are on the waiting list more than 4 years * pra i or ii \> 50% exclusion criteria: * recent recipients of any live attenuated vaccine(s) within 4 weeks * subjects who have received ivig or b cell depleting agents previously * subjects with positive result for viral hepatitis(b,c) or hiv infection * subjects with active infection * lactating or pregnant females * subjects who have history of malignancy in recent 5years * subjects who have experience of treatment for the psychiatric problem in recent 6months * subjects who have hematologic abnormality (hb \ 80iu)

Keywords: waiting list deceased donor kidney transplantation desensitization anti hla antibody
posterior wall and left atrial appendage empiric electrical isolation for non-paroxysmal atrial fibrillation

Conditions: Atrial Fibrillation

Summary: the purpose of this study is to evaluate the safety and effectiveness of empirical posterior wall isolation (pwi), left atrial appendage electrical isolation (laaei) and coronary sinus isolation (csi) when compared to pulmonary vein isolation (pvi) alone: * pvi alone, * pvi + pwi, * pvi + pwi + laaei, * pvi + pwi + laaei + csi.

the posterior wall and/or left atrial appendage empiric electrical isolation for non-paroxysmal atrial fibrillation (the plea trial) is a prospective multicenter randomized controlled study that has the overall goal of establishing the efficacy and safety of different ablation techniques for patients with persistent and long-standing persistent atrial fibrillation. the plea trial is designed to test the hypothesis whether posterior wall isolation (pwi) with pulmonary vein isolation (pvi), pwi plus left atrial appendage electrical isolation (laaei) with pvi and pwi plus laaei plus coronary sinus isolation (csi) with pvi is superior to the standard approach alone (i.e. pvi alone) in decreasing the incidence of the composite endpoint of all-cause mortality and all-atrial arrhythmia recurrences.

Eligibility criteria:
inclusion criteria: 1. provision of signed and dated informed consent form 2. stated willingness to comply with all study procedures and availability for the duration of the study 3. male or female, aged 18 or greater 4. in good general health as evidenced by medical history and diagnosed with symptomatic persistent af or long-standing persistent af. 1. persistent af will be defined as a sustained episode lasting \> 7 days and less than 1 year. 2. long-standing persistent af will be defined as a sustained episode lasting more than 1 year and less than 10 years. 3. symptoms may include, but are not restricted to, palpitations, shortness of breath, chest pain, fatigue, left ventricular dysfunction, or other symptoms, or any combination of the above. 5. at least one episode of persistent af must have been documented by ecg, holter, loop recorder, ziopatch, telemetry, trans telephonic monitoring (ttm), or implantable device within last 10 years of enrollment in this investigation. 6. patients undergoing first time procedure for af. exclusion criteria: 1. patients with paroxysmal af. • paroxysmal af will be defined as a sustained episode lasting \< 7 days (either terminated spontaneously or with pharmacological or electrical cardioversion. 2. reversible causes of af. 3. patients with contraindications to systemic anticoagulation with heparin or coumadin, direct thrombin inhibitor or factor xa inhibitors. 4. patients with left atrial size ≥ 75 mm (2d echocardiography, parasternal long axis view) 5. left atrial or laa thrombus 6. patients with severe valvular heart disease or after mitral valve replacement (bioprosthetic or mechanical). 7. patients with a life expectancy ≤ 24 months 8. cha2ds2vasc score of 0 for men and cha2ds2vasc score of 1 for women. 9. patients who are pregnant.

Keywords: catheter ablation arrhythmia recurrence embolic stroke mortality
molecular detection of efflux pump and virulence factors genes in pseudomonas aeruginosa

Conditions: Pseudomonas Aeruginosa

Summary: pseudomonas aeruginosa (pa) is a ubiquitous aerobic, non-fermentative gram-negative rod that is widely associated with nosocomial pneumonia and can lead to severe illness with poor outcomes, particularly in critically ill people due to the ability of some strains to cause lung epithelial injury and spread into the circulation. 2 in the intensive care unit, pa infection is ranked among the top five causes of the bloodstream, pulmonary, surgical site, urinary tract, and soft tissue infections.

the pathogenesis of pa infections is multifactorial, and it is frequently complicated by the bacteria's intrinsic resistance to some antimicrobial agents such as sulfonamides, tetracyclines, and trimethoprim, as well as its ability to acquire or quickly develop resistance to major classes of antibiotics such as aminoglycosides, quinolones, b-lactams, and polymyxins (bassetti et al., 2018). the efflux systems, which mediate the expulsion of antibiotics out of the cell shortly after entry, the production of enzymes to inactivate antibiotics, and the decrease in permeability across the cell wall are some mechanisms used by pa to develop antimicrobial resistance (meletis \& bagkeri, 2013). pa possesses a large number of virulence factors that play a significant role in pathogenesis and the determination of infection severity. these virulence factors act alone or in synergy with each other to cause tissue damage, necrosis, and cell death. among the virulence factors of pa, the major determinants of virulence are the type iii secretion system (t3ss) and quorum sensing (cell-to-cell signaling system). the t3ss is a needle-like complex, also known as the injectisome, that enables a bacterium to deliver different effector proteins such as exos, exot, exou, and exoy across the membrane into a host cell, altering host cell functions and increasing bacterial survival rates ( horna g and, ruiz j, 2021). in this study, we aimed to evaluate the prevalence of antibiotic resistance caused by the presence of efflux genes and some virulence factors in pseudomonas aeruginosa from clinical isolates.

Eligibility criteria:
inclusion criteria: * all patients suffering from infections that can be caused by pseudomonas aeruginosa exclusion criteria: * samples diagnosed to have organisms other than pseudomonas aeruginosa.

Keywords: efflux genes, pseudomonas , virulence, pcr
a multi-center phase 2 study to evaluate efficacy and safety of oral abexinostat as monotherapy in patients with relapsed or refractory follicular lymphoma

Conditions: Lymphoma, Follicular

Summary: an open-label, single-arm, multi-center phase 2 study to evaluate the efficacy and safety of oral histone deacetylase (hdac)-inhibitor abexinostat, as monotherapy in patients with relapsed or refractory follicular lymphoma (fl)

this is an open-label, single-arm, two-stage, multi-center, phase 2 study in patients with relapsed/refractory follicular lymphoma (fl) who have received at least two prior standard therapy lines.

Eligibility criteria:
inclusion criteria: 1. life expectancy ≥ 3 months 2. histologically confirmed grade 1, 2, or 3a follicular lymphoma (fl) 3. have received at least two prior standard therapy lines including anti- cluster of differentiation antigen (anti-cd20) antibody and cytotoxic therapy for follicular lymphoma (fl) 4. confirmed to be unresponsive to the last line of therapy (have stable disease or disease progression during treatment),or have disease progression following the last line of therapy 5. have at least one radiologically measurable lymph node or extranodal lymphoid malignant lesion as assessed by computed tomography (ct) or magnetic resonance imaging (mri); 6. eastern cooperative oncology group (ecog) performance status of 0 to 2 7. meet various hematological, liver function and renal function lab parameters exclusion criteria: 1. histologically confirmed grade 3b follicular lymphoma, or transformed diffuse large b-cell lymphoma (dlbcl) 2. current or history of central nervous system (cns) lymphoma; 3. toxicity not yet recovered from previous anti-tumor therapies 4. uncontrolled systemic infections or infections requiring intravenous antibiotics 5. have previously treated by abexinostat or other histone deacetylase (hdac) inhibitors; 6. have received steroid hormone within 7 days, chemotherapy, targeted therapy within 28 days, radiotherapy within 14 days, anti-cancer antibody therapies within 28 days 7. unable to swallow tablets, or presence of significant functional gastrointestinal disorders that may affect the oral administration and absorption of the study drug 8. have received autologous stem cell transplant within 3 months before the first dose, or allogeneic stem cell transplant within 6 months before the first dose 9. presence of active graft-versus-host disease 10. have undergone a major surgery within 28 days 11. evidence of possible human immunodeficiency virus (hiv) infection or hepatitis c virus (hcv) infection 12. have cardiac impairment as defined per protocol 13. have prior history of malignancies other than follicular lymphoma

Keywords: refractory relapsed lymph nodes
lts of siliq vs. other therapies treating of adults with moderate-to-severe psoriasis

Conditions: Psoriasis

Summary: prospective, observational study to assess the long-term safety of brodalumab compared with other therapies in the treatment of adults with moderate-to-severe psoriasis

prospective, observational study to assess the long-term safety of brodalumab compared with other therapies in the treatment of adults with moderate-to-severe psoriasis who are candidates for systemic therapy or phototherapy in the course of actual clinical care

Eligibility criteria:
inclusion criteria: 1. diagnosis and main criteria for inclusion: a subject must have moderate to severe psoriasis diagnosed by a dermatologist 2. must be at least 18 years of age or older 3. started on or switched to a systemic psoriasis treatment within the previous 12 months. fda-approved biologic treatments and select non-biologic treatments (eg, methotrexate, cyclosporine, or apremilast only) are permitted. exclusion criteria: 1. the subject is unable or unwilling to provide informed consent to participate in the registry. 2. the subject is participating or planning to participate in a clinical trial with a non-marketed or marketed investigational drug (i.e. phase i-iv drug trial). 3. the subject is restarting the eligible medication less than 12 months since receiving the last dose.
conventional fasting versus lipid/carbohydrate infusion for coronary bypass patients

Conditions: Metabolism Disorder

Summary: comparative study between conventional fasting versus overnight infusion of lipid or carbohydrate on free fatty acids and insulin in obese patients undergoing elective first time on-pump coronary artery bypass grafting.

obese patients scheduled for bypass surgery randomly assigned to three groups: group i (glucose-group): patients received 500 cc of glucose 10% containing 50 g of glucose and providing patients with 200 kcal with an osmolarity of 556 mosm/l. group ii (lipid-group): patients received 100 cc of lipid solution (soybean 30%, medium chain triglycerides 30%,olive oil 25%,fish oil 15% and 20 mg vitamine e) containing 20 g lipid and provides patients with 200 kcal with an osmolarity of 380 mosm/l. group iii (control-group): patients fasted overnight from 11 pm till 9 am except for clear fluids which were allowed till 5 am.

Eligibility criteria:
inclusion criteria: adult patients (\> 18 years) with american society of anesthesia (asa) class ii-iii, bmi 30-40, and new york heart association (nyha) functional capacities i-ii, undergoing elective on-pump coronary artery bypass grafting (cabg) using cardiopulmonary bypass (cpb). all patients were type 1a world health organisation (who)/fredrickson classification of primary hyperlipidemias. exclusion criteria: * patients with diabetes mellitus * patients on fibrates * patients type 1,2b,3,4 and 5 who/fredrickson classification of primary hyperperlipidemias * patients with history of allergic reactions to fish, egg yolk containing foods peanut or soy products * patients with carbohydrate or fat intolerance

Keywords: perioperative fasting free fatty acids coronary bypass grfting
deep tissue massage in the myofascial pain syndrome

Conditions: Massage Therapy; Myofascial Pain Syndrome

Summary: this study aims to examine the effect of deep tissue massage (dtm) on myofascial trigger point (mtrp) number, neck range of motion (rom), pain, disability and quality of life in patients with myofacial pain syndrome (mps).

a total of 88 patients with mps were screened for eligibility. of these patients, 80 who met the inclusion criteria were randomly divided into two groups using randomization with computer-generated random numbers as the control group (n=40) and dtm group (n=40). the patients were evaluated at baseline (day 0), and the end of treatment (week 4).

Eligibility criteria:
inclusion criteria: * being over the age of 18 * have at least one active trigger point * have not previously undergone local injectable anesthetic blockage or acupuncture, * complaining of pain for the last three months * getting a diagnosis of mps exclusion criteria: * patients with infectious skin disease, * using analgesic and antidepressant medication, * a history of major trauma or surgical intervention, * mini mental state examination (mmse) score ≤ 24 according

Keywords: myofascial pain syndrome neck disability pain quality of life
feasibility - infinitome

Conditions: Alzheimer Disease

Summary: the infinitome program from omniscient has the ability to identify abnormal brain networks or connectomes using resting state functional mri (rs-fmri). this technology, which visualizes brain networks in three dimensions, was originally developed to ensure neurosurgeons avoid inadvertently lesioning cognitively eloquent brain regions during surgical operations. the potential of infinitome in identifying connectome dysfunction for neurodegenerative diseases such as alzheimer's disease has yet to be explored. this diagnostic technique may play a critical role for identifying disease brain networks that may benefit from targeted interventions in clinical trials.


Eligibility criteria:
inclusion criteria: 1. patients with a diagnosis of mild, moderate, or severe alzheimer's disease 2. age: 40 - 90 years 3. patients who are clinically indicated for an mri exclusion criteria: 1. fmri contraindicated (eg. implantable device, pacemaker, metallic implants, etc.) 2. subject unable to tolerate sitting for a one hour fmri 3. other concerns as determined by the investigator
comparison of vascular risk in patients treated for obstructive sleep apnea/hypopnea syndrome

Conditions: Obstructive Sleep Apnea/Hypopnea Syndrome

Summary: a monocentric,non interventional, prospective study to compare cardiovascular risk in patients with obstructive sleep apnea/hypopnea syndrome treated with continuous positive airway pressure (cpap) and mandibular advancement orthosis.

the first-line treatment of severe obstructive sleep apnea/hypopnea syndrome (osahs) is nocturnal ventilation with continuous positive airway pressure (cpap). and the second-line treatment is the mandibular advancement orthosis (mao)\]. cpap is the most effective treatment to reduce the apnea-hypopnea index (ahi). however, its tolerance is sometimes difficult, causing many discontinuations. the purpose of this review is to evaluate a vascular morbimortality criteria: * cardiovascular: myocardial infarction, heart failure, rhythm disorder * neurological: transient or non transient stroke * ophthalmologic: anterior ischemic optic neuropathy, occlusion of the central artery or central retinal vein occlusion

Eligibility criteria:
inclusion criteria: * obstructive sleep apnea/hypopnea syndrome treated with with continuous positive airway pressure (cpap) or mandibular advancement orthosis * age ≥ 18 years old * read, write and understand the french language exclusion criteria: * patient under guardianship, deprived of liberty, safeguard of justice * refusal to participate in research

Keywords: cardiovascular risk
clinical, immunological and microbiological evaluation of experimental gingivitis and peri-implant mucositis

Conditions: Gingivitis; Mucositis

Summary: the objective of this study is to evaluate, through clinical, microbiological and immunological tests, the changes during the experimental gingivitis and mucositis model, between teeth and implants, and between patients with a history of aggressive periodontitis and healthy individuals.

the objective of this study is to evaluate, through clinical, microbiological and immunological tests, the changes during the experimental gingivitis and mucositis model, between teeth and implants, and between patients with a history of aggressive periodontitis and healthy individuals. 20 patients will be include, 10 healthy and 10 with a history of aggressive periodontitis. all patients must present the same type of implant and abutments, with prostheses in function for more than 6 months. they should also have a tooth located in the contralateral hemi-arch in a similar position, allowing a comparison with the implant. they will be submitted to the plaque-induced inflammation by suspension of oral hygiene only in the tested areas (tooth / implant), protected by a personalized stent made of plastic, according to the experimental gingivitis and mucositis model of 21 days of duration.

Eligibility criteria:
inclusion criteria: * aged ≥ 18 years, * history of aggressive periodontitis diagnosed according to the armitage classification (1999) and verified by the dental chart and time of radiographic bone emission, being in periodontal maintenance for a little more than 6 months (test group). * presence of teeth and implants (unitary prostheses) in the mouth; in a similar and counter-lateral position in the arch. the implants are the same system, including protective and dimensions. * probing depth \<5mm, in the interest sites. * plaque index ≤ 20% (silness \& löe, 1964), * healthy patients * signature of free and informed consent. exclusion criteria: * probing depth\> 5mm, in the interest sites. * history of bone loss by peri-implantitis in the implant test. * smoking; * pregnancy; * presence of systemic disorders (diabetes, hypertension, heart disease or any other condition that could contraindicate periodontal surgery); * use of medications (immunosuppressants, phenytoin or anything else that might affect mucosal healing and repair);

Keywords: aggressive periodontitis biomarkers microbiota dental implants
motivational multicomponent lifestyle interventions as a supportive treatment for depression in primary health care

Conditions: Depression

Summary: the investigators aim to examine whether a motivational multicomponent lifestyle intervention as a supportive treatment for depression has a beneficial effect on recovery from depression in a primary health care setting.

depression causes a significant global burden of disease. among depressed individuals, poor lifestyles, such as physical inactivity, unhealthy diet, and smoking, are common and play a role in the development and maintenance of depression. robust research evidence recommends applying one-component lifestyle interventions that focus on factors such as a healthy diet or exercise, as a supportive treatment for depression. currently, however, there is increasing interest in identifying the most effective multicomponent lifestyle intervention that targets more than one unhealthy lifestyle simultaneously in order to reduce depressive symptoms. the study aims to examine whether a motivational multicomponent lifestyle intervention as a supportive treatment for depression has a beneficial effect on recovery from depression in a primary health care setting. the specific study questions are as follows: 1. what is the effect of the intervention on depressive symptoms at 3- and 12-month follow-ups? 2. what is the effect of the intervention on mental well-being at 3- and 12-month follow-ups? 3. what kind of physical health do depressed patients in primary health care have? what kinds of effects does the intervention have on common physical health risk factors at 12- and 24- month follow-ups? 4. what is the effect of the intervention on health-related quality of life? 5. what is the cost-effectiveness of the intervention?

Eligibility criteria:
inclusion criteria: * adults ≥ 18 years * depression (icd-10, f32-f33) * beck depression inventory (bdi-1a) ≥ 10 points * the initiation of treatment in a primary health care center exclusion criteria: * bipolar disorder * psychosis * substance abuse * pregnancy or lactation * a long-term rehabilitative psychotherapy.
colorectal cancer screening french organizations for the follow-up after colonoscopy

Conditions: Colorectal Cancer

Summary: france is one of the european countries where the incidence of colorectal cancer is the highest among cancers for both sexes. fecal occult blood screening has been implemented since 2008. however, this screening excludes high risk people who have a 10 to 30 % risk of developing a crc during their lifetime. colonoscopy follow up of these persons is not organized, and it is up to the attending physician to recall the date of the surveillance colonoscopy. this results in a poor compliance with the recommendations by these people. a postal reminder of the surveillance colonoscopies sent by the french screening organizations to the patients should increase adherence to follow-up recommendations. the colorectal cancer screening organizations will collects from the hepatogastroenterologists (hge) informations on colonoscopies of people more than 50 years old who live in the rhone. these informations will allow to send a reminder 3 months before the date recommended by the hge. participation rate and timeliness will be assessed, as well as the severity of the lesions found. a medico-economic analysis will also be carried out.


Eligibility criteria:
inclusion criteria: * people aged 50 years or more ; * at high risk of colorectal cancer ; * living in rhône administrative departement or metropolitan lyon exclusion criteria: * person with chronic inflammatory bowel disease * colorectal cancer in diagnosis or treatment period

Keywords: mass screening colonoscopy surveillance high risk patients